As the pharmaceutical industry undergoes rapid digital transformation, the way brands communicate with their stakeholders is evolving at an unprecedented pace. From healthcare professionals and patients to regulators and investors, today’s audiences demand more than just information they expect transparency, personalization, and scientifically credible narratives delivered seamlessly across channels. In this dynamic landscape, marketing communications are no longer siloed efforts but integrated, data-driven ecosystems guided by governance and real-world evidence.
In this exclusive Q&A, Kath Darlington MBE, CEO of The Scott Partnership Ltd, shares her expert perspective on the key trends shaping pharma communications today. From the growing importance of omnichannel strategies and AI-powered insights to the critical role of trust, compliance, and patient-centricity, she outlines how organizations can navigate complexity while building meaningful, long-term engagement.
Q1. How is the pharmaceutical communications landscape evolving in response to digital transformation and changing stakeholder expectations?
Pharmaceutical communications are shifting from isolated, channel-by-channel activity to a connected, evidence-led, and governance-first model. Stakeholders (HCPs, patients, distributors, customers, regulators and investors) now expect omnichannel consistency, credible real-world data narratives, and personalised experiences delivered at speed, without compromising accuracy or compliance. Here’s what’s changing, best practices and pitfalls to avoid:
- Omnichannel is becoming the default
Audiences expect a single, coherent journey across their experience of your brand, and across all touchpoints for example email, webinars, portals, social and in person. Integrated, omnichannel campaigns ensure timely, relevant and compliant messaging, supported by dashboards that monitor performance and impact in real time. - Â Data-rich storytelling
Real-world evidence now underpins credible communication. Using proven data, supported by customer voice, in scientific educational content strengthens a brand’s value claims at launch and beyond. Complex datasets can be translated into multiple campaign elements: videos, blogs, infographics, thought leadership and expert commentary with clear sourcing and approvals. - Interactive and personalised content
Static content assets are being replaced by dynamic, adaptive formats that respond to audience interest. Using analytics and the VARK model (visual, auditory, reading/writing, kinaesthetic) ensures content meets diverse learning preferences rather than assuming one-size-fits-all. - Artificial intelligence with stronger governance
AI accelerates insight generation and content creation but demands human oversight for quality, attribution and auditability. We operate an ‘augmented intelligence’ model: using human scientific editors, source traceability, and medical-legal-ready workflows that accelerate delivery while protecting trust. But even the most sophisticated programme isn’t ‘set and forget’. Marcomms is iterative and should be continuously analysing what resonates, what underperforms, and how resources are being managed. Success depends on refinement, not automation, which is why we never advocate for an AI-only model. Human insight remains essential to interpret results, adjust parameters and maintain both impact and integrity. - Future-proofing for compliance
Regulatory expectations are evolving with digital transformation. Embedding governance, risk frameworks, audit trails, and transparent citations into every channel and asset ensures communications remain verifiable and compliant long after launch.
Q2. What are the most effective strategies for ensuring transparency and trust in pharma communications today?
Transparent marketing requires sharing complete data, including limitations, in clear accessible language. Industry surveys show that 80% of consultant-level HCPs are sceptical of pharma content when they suspect data has been cherry-picked or is incomplete[i]. This problem extends beyond healthcare. Customers want the full picture and prefer to understand and assimilate all facts, not just the ‘polished’ presentation. No brand wants to fall into the ‘They would say that, wouldn’t they?’ category.
Transparency also means communicating risks, challenges, and decisions openly. Trust grows when companies share not only successes but also the realities behind them. Leading organisations proactively explain decisions before being forced to respond reactively, an honesty that often deepens stakeholder confidence by showing both rigour and reflection.
Making science human and relatable is also central to this. Sharing authentic patient experiences and highlighting the people behind the research brings complex science to life, helping audiences connect on both emotional and intellectual levels. With 44% of people now getting pharma news from social media[ii], consistent, evidence-based engagement across all channels ensures that the same tone, facts and transparency come through wherever the audience chooses to interact.
Most importantly, many scientific brands use customers to express the true value of their products (via Customer Voice programmes). Advocates speaking on behalf of a brand add credibility and trust, and are also of course referenceable.
Q3. How are emerging technologies such as AI, data analytics, and automation reshaping communication strategies within the pharma sector?
Huge changes are underway in digital communications, with search engine optimisation (SEO) evolving towards generative engine optimisation (GEO) and large-language model optimisation (LLMO). AI, data analytics, and automation are transforming how pharma companies can design, execute, measure and report on communications.
Structured data analysis across dashboards now align marketing activity with measurable outcomes, helping budgets work harder and smarter. Regular audits uncover optimisation opportunities, from refining key expression strategies and improving tracking infrastructure to developing fit-for-purpose landing pages, all driving greater efficiency.
Automation streamlines repetitive tasks, accelerating delivery cycles and maintaining consistency across channels. AI supports content adaptation, literature summarisation and multilingual asset creation, always under human-led scientific and regulatory oversight. This combination of technology and expertise distils complex scientific data into credible, high-value communications tailored to specialist audiences.
With omnichannel expectations rising, our work increasingly links insights from analytics, media, content performance, and customer voice programmes into unified reporting structures that enhance the precision and impact of communications.
The real advantage lies in combining AI innovation with human scientific understanding, compliance awareness, and strategic collaboration to create communications that are more personalised, efficient and evidence-based.
Marketing still requires active management. Too much is at stake, from brand reputation to budget efficiency, to assume technology can run on autopilot. It’s better to progress carefully than to rely solely on unchecked automation. For example, one client used an AI platform for SEO and competitor analysis but didn’t realise the platform could not distinguish between scientific and non-scientific uses of the key expression term ‘dissolution’. The tool reported high search traffic, but most queries related to divorce, not laboratory techniques, a costly oversight that underlines why human expertise remains essential to catch such nuances and protect both performance and credibility.
Q4. What role does patient-centric communication play in shaping brand reputation and long-term engagement?
Patient-centric communication is now a reputational imperative. As patients become more informed and digitally empowered, brands that listen, involve and support them consistently are the ones that earn trust and advocacy over time. This is not just ‘good PR’, it is the operating system for long-term engagement across the product lifecycle.
Patients increasingly research their conditions before clinical visits and expect clear, accessible, information and meaningful dialogue from healthcare stakeholders. Communication that is factual, transparent, inclusive and empathetic directly shapes how brands are perceived and whether patients remain engaged across the treatment journey.
Effective patient-centric communication means co-creating content with patient groups, offering continuous support programmes rather than one-off campaigns, and using consented data to deliver relevant, responsible personalisation. Brands that provide practical tools, such as trackers, onboarding guides, and symptom diaries, and share updates on how patient feedback has driven change tend to build the strongest loyalty and trust.
At The Scott Partnership, we translate this philosophy into action by mapping unmet information needs and turning them into clear messaging frameworks. Our plain-language content systems, spanning FAQs, videos, explainers, and GEO-optimised blogs, sit alongside scientific outputs with full citation and compliance. We co-create ethical, consented stories featuring patients and experts to humanise complex science, and we orchestrate omnichannel delivery so consistent, evidence-based information meets patients wherever they look and whichever channel they prefer.
Measurement, medical-legal governance, and transparency reporting underpin every step to ensure credibility and continuous improvement.
Q5. In your view, what are the key emerging trends that will define pharma communications over the next 3–5 years?
- Governance-led adoption of advanced and agentic AI: Automation and generative tools will expand, but the differentiator will be compliant, well-governed workflows with human oversight.
- Evidence-linked measurement: Pharma companies increasingly expect communications to tie directly to behavioural and commercial outcomes. We anticipate greater emphasis on dashboards that connect digital, content, search, PR, and lead generation performance into decision-ready reporting.
- Mature omnichannel orchestration: Communications will become fully journey-driven, integrating scientific content, media, events, digital channels and stakeholder engagement into cohesive experiences. Modular content systems and more dynamic personalisation will become essential.
- Scientific storytelling for specialised therapies: As pipelines evolve, demand will grow for communications that translate complex mechanisms, data and value narratives into accessible, resonant stories for diverse audiences. Voice of Customer leaps into forefront here to enable trusted third parties to talk on a brand’s behalf: scientists trust other scientists above brands, and testimonial voices provide great citations for LLMO. We have already built an LLMO content model to support clients in optimising their websites and existing content for better GEO, improved AI parsing and retrieval.
- Global + Local Strategy One-size-fits-all approaches are dead. Differences between geographic behaviours requires cultural intelligence and localized relevance.  There are so many platforms that dominate one geography but not another (WeChat, Naver, Line, Xing even Google and LinkedIn etc) that it is imperative to make active decisions about strengthening localised support to best communicate.
Q6. What advice would you offer to pharma leaders looking to future-proof their communication strategies?
Your marketing programmes are not static – you cannot set them up and leave them to run. We often see clients overlook the basics, for instance, leaving credit cards linked to campaign platforms without monitoring performance, and end up wasting thousands of dollars though failing to monitor and manage. Smart technology doesn’t replace active management, it makes it more essential than ever.
AI has an important role to play within your workflow but in reality, will actually demand more performance management, not less to prioritise decision-making and optimal deployment.
It’s worth making sure your current marketing is working optimally, benchmark before you improve. To learn the value of this, read our recent digital marketing audit for Magnitude Biosciences here: https://www.scottpr.com/case-study-magnitude-biosciences/
[i] https://www.graphitedigital.com/downloads/trust-hcp-engagement
[ii] Ipsos/ABPI UK Pharma Reputation Index, 2024. Base: 2,000 UK adults for general population data; 427 respondents for information sources data; 1,872 respondents aware of pharma companies for trust and understanding metrics.
